Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients (AVD-Rev)

This study is ongoing, but not recruiting participants.
Information provided by:
University of Cologne Identifier:
First received: September 8, 2009
Last updated: January 25, 2013
Last verified: January 2013

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Condition Intervention Phase
Hodgkin Lymphoma
Drug: Doxorubicine
Drug: DTIC
Drug: Lenalidomide
Drug: Vinblastine
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients

Resource links provided by NLM:

Further study details as provided by University of Cologne:

Primary Outcome Measures:
  • Dose limiting toxicities (DLT) [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall response rate (ORR) [ Designated as safety issue: No ]
  • Progression free survival (PFS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: April 2010
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Doxorubicine
    50mg/m2 day 1 + 15
    Drug: DTIC
    375mg/m2 day 1 + 15
    Drug: Lenalidomide
    day 1 - 21
    Drug: Vinblastine
    6mg/m2 day 1 + 15

Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hodgkin Lymphoma, intermediate or advanced stage
  • Age >60 and <75 years
  • ECOG 2 or better
  • No major organ dysfunction
  • Ability to take aspirin or LMW Heparin

Exclusion Criteria:

  • HL as composite lymphoma
  • Prior use of lenalidomide
  • Prior use of chemo- or radiotherapy
  Contacts and Locations
Please refer to this study by its identifier: NCT01056679

1st Dept. of Medicine, Cologne University Hospital
Cologne, NRW, Germany, 50924
Sponsors and Collaborators
University of Cologne
Principal Investigator: Andreas Engert, Prof. University of Cologne
  More Information

Additional Information:
No publications provided Identifier: NCT01056679     History of Changes
Other Study ID Numbers: AVD-Rev
Study First Received: September 8, 2009
Last Updated: January 25, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on April 14, 2014